ReviewMedGenMed : Medscape general medicine2007
Peritoneal mesothelioma: a review.
Review in MedGenMed : Medscape general medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01160458 (Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy), which is not on this map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Radical multimodality therapy for malignant pleural mesothelioma.The Cochrane database of systematic reviews · 2018Pooled it
- Diffuse peritoneal mesothelioma presenting with the appearance of mesenteric panniculitis: A case report.Oncology letters · 2026Article
- Article
- Article
- Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.Frontiers in oncology · 2026Article
- Demographic disparities in temporal trends and geographic variations of malignant pleural and peritoneal mesothelioma incidence in Pennsylvania, 1990-2019.Cancer causes & control : CCC · 2025Article
- Malignant peritoneal mesothelioma as a secondary cancer following radiotherapy for cervical cancer: a case report and literature review.Gynecologic oncology reports · 2025Article
- Time till pleuropulmonary recurrence for mesothelioma and high grade appendiceal neoplasm after CRS/HIPEC.Pleura and peritoneum · 2025Article
- Twice as Effective? Pressurized Intra-Thoracic Aerosol Chemotherapy: New Frontiers in Pleural Mesothelioma.Medical sciences (Basel, Switzerland) · 2025Article
- 8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines.Journal of cellular and molecular medicine · 2025Article
- Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.JTO clinical and research reports · 2025Article
- Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review).International journal of oncology · 2025Review
- Analysis of TERT mRNA Levels and Clinicopathological Features in Patients with Peritoneal Mesothelioma.Cancers · 2025Article
- Development and validation of a prognostic nomogram for patients with malignant peritoneal mesothelioma.Frontiers in oncology · 2025Article
- Incidence, mortality and survival of pleural mesothelioma in Zurich between 1981 and 2019, Switzerland.Journal of thoracic disease · 2024Article
- Spatial Landscape of Malignant Pleural and Peritoneal Mesothelioma Tumor Immune Microenvironments.Cancer research communications · 2024Article
- Dual Malignancies Discovered: A Rare Case of Malignant Peritoneal Epithelioid Mesothelioma and Lung Adenocarcinoma.Cureus · 2024Article
- Asbestos ban policies and mesothelioma mortality in Greece.BMC public health · 2024Article
- Lung cancer in patients who have never smoked - an emerging disease.Nature reviews. Clinical oncology · 2024Review
- Biphasic Peritoneal Mesothelioma Is a Rare Tumor and a Diagnostic Challenge: A Case Report.Cureus · 2024Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant peritoneal mesothelioma (MPM) is a rare aggressive tumor of the peritoneum, regarded as a universally fatal disease. It is poorly described and the knowledge of its natural history is very limited. Occupational and environmental asbestos exposure still remains a public health problem around the world. The incidence has increased in the past 2 decades. Only 20% to 33% of all mesotheliomas arise from the peritoneum itself; the pleura is the most common site of origin.
Indexed as
Identifiers
17955087PMC1994863W102573316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.